FDA flags cardiovascular risks tied to Novo's degludec

11/7/2012 | Reuters

The FDA highlighted uncertain heart risks tied to Novo Nordisk's long-acting insulin degludec. The drug could raise by 10% the risk of unstable angina, nonfatal stroke, nonfatal heart attack and cardiovascular death, according to the initial assessment of an analysis of 16 studies. The added risk was found to be higher at 30% in a later update.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC